Arvinas
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
Corporate information
- Company entity
- Arvinas, Inc.
- Headquarters / principal office
- New Haven, ConnecticutSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2013 ↗
- Ownership / capital status
- Publicly tradedPublicly traded ↗
- Official corporate reference
- https://www.arvinas.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.